Use of 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Rare Head and Neck Cancers by Roh, Jong-Lyel et al.
103
INTRODUCTION
Head and neck cancers (HNC) are the sixth most common type
of human cancer worldwide. Squamous cell carcinomas form the
major type of the extracranial HNCs, followed by lymphomas
and differentiated thyroid cancers (1). Due to the higher gly-
colytic rates of many neoplasms relative to normal tissue, the
glucose analog 
18F-fluorodeoxyglucose (FDG) can be used to
detect tumors, and positron emission tomography (PET) using
FDG has been utilized in patients with HNCs for initial staging,
management of recurrent cancers, and therapeutic monitoring
(2-5). Since head and neck tumors generally have high uptake
of FDG (6), FDG PET can detect HNCs that might not be reveal-
ed by conventional imaging methods, including computed tomog-
raphy (CT), magnetic resonance imaging (MRI), and ultrasonog-
raphy (7-9). Although studies of salivary cancers, melanomas,
basal cell carcinomas, and sarcomas arising in the head and neck
region have suggested that FDG PET may be clinically useful in
the staging, histologic grading, and post-treatment monitoring
of patients with these tumors (10-13), the role of FDG PET in
rare HNCs is still unclear, due to the rarity of these cancers. We
therefore evaluated the role of FDG PET for staging and moni-
toring patients with rare HNCs, including melanomas, basal cell
carcinomas, sarcomas, and olfactory neuroblastomas (esthesioneu-
roblastomas).
Objectives. The clinical utility of 
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has been demon-
strated in major head and neck cancers (HNCs) but is unclear in rare HNCs. We therefore evaluated FDG PET in
the management of patients with rare HNCs.
Methods. FDG PET and CT/MRI scanning were performed at the initial staging and/or the follow-up in 24 patients with
rare HNCs, 10 with melanoma, 9 with sarcoma, 3 with olfactory neuroblastomas, and 2 with basal cell carcinoma.
The diagnostic accuracy of CT and FDG PET for detecting primary tumors and metastases were compared with a
histopathologic reference. The association between the PET results and the clinicopathologic parameters predict-
ing tumor invasion, histologic grade and disease-free survival (DFS), was assessed.
Results. The overall accuracies of FDG PET and CT/MRI were 92% and 79%, respectively, for detecting primary tumors
and 91% and 74%, respectively, for nodal metastases, but the differences were not significant due to the small
number of patients. The sensitivity and specificity of FDG PET for detecting distant metastases and second prima-
ry tumors were 100% and 87%, respectively. Follow-up FDG PET correctly diagnosed locoregional recurrence in
all 12 patients, as shown by biopsy, and distant metastases in 6 patients. However, thickness of melanoma, histo-
logic grade of sarcoma, and DFS were not associated with tumor FDG uptake.
Conclusion. FDG PET may be useful for staging, posttreatment monitoring, and detection of distant metastases and sec-
ond primary tumors in patients with rare HNCs.
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Original ArticleMATERIALS AND METHODS
Patient population and treatment
Patients presenting with rare HNCs between March 2000 and
December 2005 were enrolled in this study. All patients with
previously untreated or recurrent rare HNCs were assessed by
biopsy, CT and whole body FDG PET before treatment for pre-
viously untreated or recurrent rare HNCs. Patients with squa-
mous cell carcinoma, lymphoma, thyroid cancer, salivary gland
cancer, nasopharyngeal carcinoma, metastatic lesion with pri-
mary tumor outside the head and neck, and metastasis from
unknown primary squamous cell carcinoma or adenocarcinoma
were excluded, as were patients not assessed by FDG PET prior
to treatment or during follow-up and patients with inadequate
follow-up information. For patients with more than one FDG
PET scan, the pretreatment or the most relevant follow-up scan
was included. Final diagnosis was based on pathologic confirma-
tion of the tumor and adequate follow-up. This study was review-
ed and approved by the Institute’s Ethics Review Committee.
Twenty-four patients with skin cancer (n=12), sarcoma (n=9),
or olfactory neuroblastoma (n=3) in the head and neck area were
included in the final analysis (Table 1). The patient cohort con-
sisted of 9 men and 15 women, of mean age 51 yr (range, 11-
81 yr). FDG PET scanning was performed in 20 patients with
previously untreated tumors during initial staging and in 4 with
primary or cervical nodal recurrence at follow-up (4-18
months) after initial treatment. Staging of olfactory neuroblas-
tomas and other HNCs were as described (Table 1) (14, 15).
Nineteen patients underwent resection of the primary tumor,
with or without neck dissection. Four patients with cervical nodal
recurrence of melanoma underwent only neck dissection. One
patient with olfactory neuroblastoma refused definitive surgery
and so received chemoradiotherapy. Supraomohyoid neck dis-
section (levels I-III) was performed in 11 patients suspected of
having high-grade or locally invasive tumors and clinically neg-
ative nodal involvement. Modified or radical neck dissection
104 Clinical and Experimental Otorhinolaryngology  Vol. 1, No. 2: 103-109, June 2008
Sex/
age















Table 1. FDG PET and treatment outcomes of patients with rare head and neck cancers
1 M/52 Mal melanoma Nose pT4aN2bM0 Initial + + + + -- S+RT+C Reg 66 NED
2 F/60 Mal melanoma Palate, R pT4aN2bM0 Initial + + + + -- S+RT+C Loc, Ds 38 AD
3 F/65 Mal melanoma MS, L pT2aN0M0 Initial + + -- - - S+RT - 13 NED
4 F/81 Mal melanoma NC, L pT4bN0M0 Initial + + -- - - S+RT Loc 13 AD
5 F/40 Mal melanoma NC, L pT2bN1bM0 Initial + + + + -- S+RT - 14 NED
6 M/58 Mal melanoma NC, L pT2aN0M0 Initial - + -- - - S Loc, Ds 31 DOD
7 M/47 Mal melanoma Unknown pTxN2bM0 Initial -- ++ -- S+RT Reg 12 AD
8 F/71 Mal melanoma Unknown pTxN2bM0 Initial -- ++ -- S - 30 NED
9 F/64 Mal melanoma Earlobe, L pTxN2bM0 Follow -- ++ --S+C Reg, Ds 78 DOD
10 F/48 Mal melanoma Palate, L pTxN1bM0 Follow -- + + Thyroid FTC S+RT Reg 178 NED
11 F/73 Basal cell ca Upper lip pT4N0M0 Initial + + -- - - S+C Loc 26 AD
12 M/65 Basal cell ca Orbit, L pT4N0M0 Initial + + --Med - S - 61 NED
13 F/37 Rhabdomyo- PPF,  L pT2bN0M0 Initial + + + --- S+RT+C Loc, Ds 14 DOD
sarcoma
14 M/38 Leiomyosar- Gingiva,  R pT1bN0M0 Initial + + -- - - S+RT - 53 NED
coma
15 M/44 Synovial sarcoma PPx, L pT2bN0M0 Initial + + -- - -S+RT+C Ds 19 DOD
16 F/59 MFH Neck, L pT2bN1M0 Initial + + + + -- S+RT - 34 NED
17 M/48 SC sarcoma Neck, R pT1bN0M0 Initial + + -- Stomach - S - 36 NED
18 F/35 Osteosarcoma Mandible, R pT2N0M0 Initial + + -- - -S+RT+C Ds 30 AD
19 F/22 URC sarcoma Scalp, L pT1aN0M0 Initial - ++ --- S - 32 NED
20 M/49 Liposarcoma Neck, L pT2bN0M0 Follow + + -- - - S+RT Loc 92 NED
21 F/30 SRC sarcoma Neck, L pT1bN0M0 Follow + + -- Thyroid FCL S+RT+C Loc 171 NED
22 M/57 ON NC, PNS, R Kadish B Initial + + -- - -S+RT+C - 40 NED
23 F/65 ON NC, PNS, IC Kadish C Initial + + + + -- S+RT - 19 NED
24 F/11 ON NC, PNS, IC Kadish C Initial + + + + -- C+RT Residual 12 AD
AD: alive with disease; C: chemotherapy; ca: carcinoma; distant/2nd: distant metastases or second primary cancers; DOD: died of disease; Ds: distant; Dx,
diagnosis; mal: malignant; FCL: follicular cell lesion; FDG: 
18F-fluorodeoxyglucose; FTC: follicular thyroid carcinoma; L: left; Loc: ocal; Mal: malignant; Med:
mediastinal lymph nodes; MFH: malignant fibrous histiocytoma; MS: maxillary sinus; NC: nasal cavity; NED: no evidence of disease; ON: olfactory neurob-
lastoma (esthesioneuroblastoma); PET: positron emission tomography; PNS: paranasal sinus; PPF: pterygopalatine fossa; PPx: parapharyngeal space; R:
right; Reg: regional neck; RT: radiotherapy; S: surgery; ca: carcinoma; SC: spindle cell; SRC: small round cell; URC: unclassified round cell.
*Stage at PET scan (14, 15). 
� Time at last follow-up after initial treatment.(levels I-V) was performed in 11 patients suspected of having
nodal involvement or extracapsular nodal spread. Bilateral neck
dissection was performed in one patient suspected of having
bilateral disease. Retropharyngeal nodes were dissected in 3
patients suspected of having metastases to the nodes and paro-
tidectomy was performed at the tumor-affected sides of 4 pati-
ents. Seventeen of 24 patients (71%) received postoperative
locoregional radiotherapy (mean dose, 63.4 Gy; range, 34.2-
70.2 Gy), using single daily fractions, and 10 patients received
chemotherapy.
Imaging
All patients underwent PET with an ECAT HR+ scanner (Sie-
mens/CTI, Knoxville, TN, USA), with an in-plane spatial reso-
lution of 4.5 mm and an axial field view of 15.5 cm. Patients
fasted for at least 6 hr prior to FDG PET scanning, and their
blood glucose concentrations measured; patients with diabetes
mellitus had to have blood glucose levels below 150 mg/dL prior
to the scan. All patients were rested for at least one hour before
FDG PET scan. Beginning approximately 60 min after intra-
venous injection of about 555 MBq FDG, whole-body imaging
was performed with the patient in the supine position. Data were
reconstructed into coronal, sagittal, and transverse sections and
a three-dimensional rotating projection. The standardized uptake
value (SUV) was calculated using the attenuation-corrected
images, the amount of injected FDG, the lean body weight of
each patient, and the cross-calibration factors between FDG
PET and the dose calibrator.
All patients also underwent CT of the head and neck, using a
LightSpeed QX/i scanner (GE Medical Systems, Milwaukee, WI,
USA) or a Somatom Sensation 16 (Siemens Medical Solutions,
Forchheim, Germany), with a slice thickness of 3-5 mm. Patients
were placed in the supine position, and CT was performed with
contrast-enhanced axial images parallel to the occlusal line from
the skull base to the upper chest. In selected patients, direct coro-
nal or coronal reconstruction images were also obtained. MRI
was performed in 8 patients with a 1.5-T unit (Siemens Medical
Solutions) using the spin-echo technique and a slice thickness of
5 mm. Unenhanced T1-weighted images were acquired in the
coronal and axial planes and T2-weighted fat-suppressed fast-
spin-echo images were also obtained. After injection of 0.1 mmol
gadolinium/kg body weight, T1-weighted fat-suppressed axial,
coronal, and sagittal images were sequentially obtained.
Image interpretation and histological examination
All FDG PET images were re-reviewed by an experienced nuclear
medicine staff member. The degree of suspicion of malignant
involvement was based on qualitative visual interpretation of
the images and the determination of maximal SUV, a semiquan-
titative measure of relative FDG uptake within the regions of
interest. FDG PET images were reviewed to calculate the SUV,
and the slice containing the tumor was selected. The maximum
SUV of primary tumors was used as a reference for correlation
with survival.
CT/MRI results were interpreted by experienced radiologists.
Nodes were considered metastatic if central necrosis or inho-
mogeneous enhancement was present, if their longest axial diam-
eter was over 1.5 cm in the jugulodigastic regions or over 1 cm
in other cervical regions, or if there was a cluster of 3 or more
lymph nodes of borderline size. The FDG PET and CT/MRI read-
ers were blinded to each other’s results, as well as to pathology
results.
To correlate CT/MRI and FDG PET results, the primary tumor
sites and the sides and levels of the involved neck or retropha-
ryngeal nodes were recorded (16). Primary tumors and lymph
nodes were dissected from the specimens and assessed histopa-
thologically. Local invasiveness, the histological grade of the pri-
mary tumors, the total number of lymph nodes, and the pres-
ence or absence of tumor within these nodes and at the primary
sites were recorded by an experienced pathologist.
Statistical analysis
The sensitivity, specificity, and predictive values of each imag-
ing method for detecting primary tumors and metastatic nodes
were calculated and compared with histological results. A two-
tailed P value was used to assessed according to the FDG PET
with CT/MRI. The 
2 test, or Mann-Whitney or Kruskal-Wallis
test was used for categorical data or mean analyses. Correlation
between maximal SUV and other significant variables (tumor
size and thickness, histologic grade, stage) was analyzed using
Spearman correlation coefficients (r).
Actuarial disease-free survival (DFS) and overall survival
rates were calculated by the Kaplan-Meier method. Persistent
or recurrent tumor was documented by CT/MRI or FDG PET
scanning. The time interval for local control and survival end-
points was calculated from the first day of initial treatment until
the date of an event or of the last follow-up. The log-rank test
was used to assess the correlation of these end points with SUV
and the clinicopathologic variables. A P value less than 0.05 was
considered statistically significant.
RESULTS
Two patients had melanomas in cervical nodes but no proven
primary sites. The most common sites of these rare HNCs were
the nasal cavity and neck (Table 1). Three patients had stage I
disease, five stage II, 12 stage III, and one stage IV; a patient
with olfactory neuroblastoma was in Kadish stage B and two
were in stage C disease. Ten patients (42%) had metastases to
the cervical or retropharyngeal lymph nodes. Primary tumors
were completely removed in 20 of the 23 patients who under-
went surgery; their mean±SD size in the largest histopatholog-
ic dimension was 4.5±2.5 cm. Three patients had microscopic
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ness of primary melanoma was 3.6±2.7 mm; of the patients
with sarcoma, 4 each had low and high grade tumors.
The overall sensitivity of FDG PET and CT/MRI for detect-
ing primary tumors was 18/20 (90%) and 17/20 (85%), respec-
tively, and their specificity was 4/4 (100%) and 2/4 (50%),
respectively (Table 2). The positive and negative predictive val-
ues of FDG PET were 11% and 27% higher, respectively, than
those of CT/MRI. None of these differences, however, was sta-
tistically significant using the McNemar test (P>0.05). CT/MRI
was unable to detect definitive primary lesions in 3 patients
with melanoma or sarcoma; of these, 2 were correctly detected




TP FP FN TN
Factor on which analysis
was based
% (95% Confidence interval)
Specificity PPV NPV Sensitivity
Table 2. Results of CT/MRI and PET for detecting primary tumors and metastatic nodal diseases in patients with rare head and neck cancers
PET: positron emission tomography; TP: true-positive; FP: false-positive; FN: false-negative; TN: true-negative; PPV: positive predictive value; NPV: negative
predictive value; ON: olfactory neuroblastoma (esthesioneuroblastoma); NA: not applicable; RP: retropharyngeal.
*One patient was excluded because of a lack of node dissection.
Primary tumors
Overall (n=24) CT/MRI 7 2 3 2 85 (62-96) 50 (6-93) 89 (66-98) 40 (5-85)
FDG PET 8 0 2 4 90 (68-98) 100 (39-100) 100 (81-100) 67 (22-95)
Skin cancers (n=12) CT/MRI 7 2 1 2 88 (47-99) 50 (6-93) 78 (39-97) 67 (9-99)
FDG PET 7 0 1 4 88 (47-99) 100 (39-100) 100 (59-100) 80 (28-99)
Sarcomas (n=9) CT/MRI 7 0 2 0 78 (39-97) NA 100 (59-100) 0 (0-84)
FDG PET 8 0 1 0 89 (51-99) NA 100 (63-100) 0 (0-97)
ON (n=3) CT/MRI 3 0 0 0 100 (29-100) NA 100 (29-100) NA
FDG PET 3 0 0 0 100 (29-100) NA 100 (29-100) NA
Patients with positive findings in RP or cervical nodes
Overall (n=23)
CT/MRI 8 5 1 9 89 (51-99) 64 (35-87) 62 (31-86) 90 (55-99)
FDG PET 9 2 0 2 100 (66-100) 86 (57-98) 82 (48-97) 100 (73-100)
Skin cancers (n=12) CT/MRI 6 2 1 3 86 (42-99) 60 (14-94) 75 (34-96) 75 (19-99)
FDG PET 7 0 0 100 (59-100) 100 (47-100) 100 (59-100) 100 (47-100)
Sarcomas (n=9) CT/MRI 1 3 0 100 (2-100) 63 (24-91) 25 (0-80) 100 (47-100)
FDG PET 1 2 0 100 (2-100) 75 (34-96) 33 (0-90) 100 (54-100)
ON (n=2)* CT/MRI 1 0 0 100 (2-100) 100 (2-100) 100 (2-100) 100 (2-100)
FDG PET 1 0 0 100 (2-100) 100 (2-100) 100 (2-100) 100 (2-100)
Fig. 1. Detection of primary tumor and nodal
metastasis by FDG PET. (A-C) Whole body
FDG PET showing focal FDG uptake in
the left anterior nasal cavity (arrowheads)
and upper neck (arrows) of a 40-yr-old
melanoma patient (case no. 5). (D, E) Axial
CT scans showing the ab- sence of sig-
nificant lesions in the nasal cavity and upper





Eby FDG PET (Fig. 1). CT/MRI also falsely diagnosed primary
lesion sites of the 2 patients with cervical nodal melanomas with
unknown primary site: both were negative on FDG PET. The
latter method yielded no false-positives, but 2 false-negatives,
one patient with melanoma and the other with an unclassified
round cell sarcoma, with the largest tumor diameters less than
2.5 cm (Table 2). One of these primary lesions was detected by
CT/MRI.
Ten of 23 patients (42%) had cervical (n=8) or retropharyn-
geal (n=2) nodal metastases: 9 were diagnosed by node dissec-
tion and 1 by fine-needle aspiration biopsy (case no. 24). When
we analyzed the correlation of CT/MRI, FDG PET, and histol-
ogy in the 23 patients who underwent surgery for nodal diseases,
we found that the overall sensitivity, specificity, and positive
and negative predictive values of FDG PET for detecting nodal
metastases were 10-22% higher than those of CT, but the dif-
ferences were not significant by the McNemar test (P>0.05)
because of the small number of patients (Table 2). FDG PET
accurately detected the presence or absence of nodal metastases
in 21 of 23 patients (91%), whereas CT was accurate in 17 (74
%). FDG PET falsely interpreted neck disease in 2 of 23 patients
(7%); the two false-positives were due to reactive or inflamma-
tory nodes and proximity to the primary lesion of a sarcoma
patient (Fig. 2).
FDG PET scans suggested distant metastases and second pri-
mary cancers in 1 and 3 patients, respectively; of these, only
one had a true second primary malignancy in the thyroid gland
(case no. 10). The PET-positive findings were confirmed by fur-
ther imaging work-ups and biopsy, and PET-negative findings
by follow-up imaging. The overall sensitivity, specificity, and
positive and negative predictive values of FDG PET for detect-
ing distant metastases or second primary tumors were 100%,
87%, 25%, and 100%, respectively.
The maximum SUV was 5.1±3.0 (range, 1.4 to 12.0) in pri-
mary tumors and 6.1±3.4 in cervical diseases (range, 1.9-12.0).
Mean tumor or nodal SUV did not correlate with age, sex, nodal
positivity, or tumor pathology (P>0.05). The SUV of primary
tumors did not statistically correlate with the size or stage of
tumor, melanoma thickness, or the grade of sarcoma (P>0.05).
At last follow-up, 14 patients were alive without disease and
6 were alive with disease. The mean follow-up for surviving
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Fig. 2. False results of both FDG PET and MRI. (A, B) Whole body FDG
PET showing focal FDG uptake in the left posterior neck (black arrows)
and no other sites of a 22-yr-old sarcoma patient (case no. 19). (C)
Gadolinium-enhanced axial T1-weighted MR image showing a strong-
ly enhancing lymph node (white arrow). Surgical pathology revealed
a 1-cm-sized, round cell sarcoma in the skin and superficial subcuta-
neous tissue on the left scalp but no cervical nodal metastases. The




Fig. 3. Detection of regional recurrence and distant
metastasis by FDG PET. (A-C) Whole body FDG PET
showing focal FDG uptakes in the left neck (arrows)
and L1 vertebra (arrowheads) of a 64-yr-old melanoma
patient (case no. 9). (D) Axial CT scan showing a bony
metastatic lesion in the left side of the L1 vertebral body. A C
B Dpatients was 48.5±47.8 months (range, 12 to 178 months).
Twelve patients presented with persistent or recurrent locore-
gional diseases on FNAB, CT/MRI and FDG PET and 6 pre-
sented with distant metastases; of these 4 died of diseases. At 4
years, actuarial locoregional control was 59%, DFS was 56%,
and overall survival was 83%. Univariate analysis for DFS show-
ed that age, sex, local invasion, thickness of melanoma, pathol-
ogy grouping, histologic grades of sarcoma, SUV category (>5.0
or ≤5.0), and stage were not statistically significant (P>0.05).
All patients received follow-up CT scanning and FDG PET
scanning. Follow-up FDG PET imaging correctly diagnosed
locoregional recurrence in all 12 patients, as shown by biopsy,
and distant metastases in 6 patients (Fig. 3).
DISCUSSION
FDG PET is a well-established, noninvasive method for diagnos-
tic imaging of malignancies that show increased glucose utiliza-
tion compared with normal tissues (6). In patients with HNCs,
FDG PET has been used clinically for tumor staging and restag-
ing, monitoring treatment, and predicting prognosis (2-5). FDG
PET has been found to be superior to conventional imaging in
evaluating patients with common HNCs, including squamous
cell carcinomas, lymphomas, and salivary cancers (4, 7-10). Our
findings also suggest that FDG PET might be superior to conven-
tional imaging in staging of miscellaneous cancers of the head
and neck, including melanomas, basal cell carcinomas, sarco-
mas, and olfactory neuroblastomas. The sensitivity and speci-
ficity of FDG PET were somewhat higher than those of CT/MRI,
although not significantly different from CT/MRI, due to the
small numbers of patients.
Melanoma is a highly malignant tumor of the skin or, more
rarely, of the mucosal surface, of the head and neck (17). Altho-
ugh FDG PET has been shown to detect metastases at unusual
sites that are easily missed by conventional imaging modalities,
the former is of limited use in patients with early-stage disease
and cannot replace sentinel node biopsy (18-21). Although FDG
PET was not able to detect the primary tumor site in 1 of our 6
melanoma patients, it detected cervical nodal metastases in all 7
patients with metastases, in one of whom conventional imaging
failed to identify the metastases. FDG PET was shown to visual-
ize locoregional and distant metastases in 10 patients with mucos-
al malignant melanoma of the head and neck (12), as well as to
image and identify basal cell carcinoma, especially the nodular
histologic subtype (13). 
Sarcomas are a heterogeneous group of connective tissue
malignancies arising in soft tissues and bone (22). Reports have
shown a relationship between tumor grading and FDG avidity,
and FDG PET may have a prognostic role in the management
of sarcomas (23-25). In agreement with previous findings, we
found that FDG PET was highly accurate in detecting primary
tumors (8/9) and cervical metastases (7/9) (11).
Olfactory neuroblastomas arise from olfactory neuroepitheli-
um, which extends from the roof of the nose to the nasal cavi-
ty, paranasal sinus, and sometimes to the intracranium (26).
Tumor stage is dependent on the degree of local extension (14),
and these tumors may also spread regionally to the neck, with
an incidence ranging from 5% to 100% (27). To our knowl-
edge, this study is the first to indicate that FDG PET may have
a role in detecting primary and metastatic disease and in initial
tumor staging of olfactory neuroblastoma.
FDG PET has been shown effective not only in identifying
locoregional lesions but in detecting unsuspected distant metas-
tases (28), and this method has been reported superior to con-
ventional imaging modalities for detecting second primary malig-
nancies (29). Although we found that FDG PET was accurate in
detecting distant metastases and second primary cancers at ini-
tial staging and follow-up, it also identified several false positives.
Therefore, to avoid false positive results, metastatic or second
primary lesions showed by FDG PET in patients with these rare
HNCs should be evaluated by additional diagnostic methods.
To our knowledge, this study is the largest series to date eval-
uating FDG PET in patients with rare HNCs (11-13). Although
we attempted to minimize potential biases by comparing FDG
PET and CT/MRI results with those obtained histopathological-
ly, our study may have been limited by the inclusion of various
pathologies, the small number of patients, and all initial and fol-
low-up data. No statistical correlations between FDG uptake
and the thickness of melanoma or the grade of sarcoma may
result from the small number of these patients. In addition, the
retrospective design may have important limitations. Another
source of potential bias was that we did not routinely perform
pre- and post-treatment FDG PET in all patients with rare HNCs
during the study period. Nevertheless, our results indicate that
FDG PET may have a role in the management of patients with
rare HNCs.
In conclusion, we have investigated the clinical utility of FDG
PET in patients with rare HNCs. FDG PET may have potential
roles in the staging, posttreatment monitoring, and detection of
distant metastases or second primary tumors, thus affecting the
management of these patients. Histological grade and survival
outcomes in these rare HNCs were not associated with FDG
uptake, due to the small number of patients. Additional studies,
in larger numbers of patients, are warranted. A more system-
atized policy or clinical protocol for performing follow-up PET
to these patients may be also required.
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